Latest Breaking News On - Mixed model repeated measures - Page 1 : comparemela.com

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a good safety and tolerability profile throughout the study Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).

Jack khattarJacka khattarJim kellyPeter vozzoExchange commissionSecurities exchangeDrug administrationSupernus pharmaceuticals incSupernus pharmaceuticalsSymptom rating scaleClinical global impressionComplete response letterNew drug applicationChief executive officerMixed model repeated measuresFull analysis set